TSC1 and central nervous system cancer: Our findings also reveal drug-actionable mutations [3], and advocate for therapeutic targeting of the MAPK/TSC/mTOR pathway for high-grade epithelioid gliomas that may otherwise behave aggressively when treated only with conventional therapy.